^
Association details:
| Biomarker: | MET exon 14 mutation + MET overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tabrecta (capmatinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
986P - Response to capmatinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping (METex14) mutation: Whole transcriptome analysis from phase II GEOMETRY Mono-1 study
Published date:
09/05/2022
Excerpt:
Pts with advanced METex14 NSCLC received oral capmatinib 400 mg twice daily….1L pts with high MET expression had significantly longer PFS than 1L pts with low MET expression (p<0.01, Cox model).
Trial ID:
